PharmaShots | Incisive News in 3 Shots

Subscribe Now

Chronic Spontaneous Urticaria (CSU)

Novartis' Ligelizumab (QGE031) Receives the US FDA's Breakthrough Designation for Patients with Chronic Spontaneous Urticaria

Novartis' Ligelizumab (QGE031) Receives the US FDA's Breakthrough Designation for Patients with Chronic Spontaneous Urticaria

January 15, 2021

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us